MOH — authorised 31 July 2009
- Marketing authorisation holder: JANSSEN PHARMS
- Status: likely_approved
MOH authorised Invega Sustenna on 31 July 2009
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH authorised it on 31 July 2009.
JANSSEN PHARMS holds the UAE marketing authorisation.